Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:FULC NASDAQ:SLGL NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.64-4.1%$4.77$3.16▼$11.89$62.50M-0.91287,087 shs78,014 shsFULCFulcrum Therapeutics$3.72-1.1%$4.25$2.83▼$15.74$247.87M3.011.81 million shs572,842 shsSLGLSol-Gel Technologies$81.96+1.8%$74.88$10.48▼$97.97$230.30M1.1235,715 shs24,517 shsTRDAEntrada Therapeutics$5.85-3.3%$6.79$4.93▼$16.45$227.10M-0.26438,722 shs566,335 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate0.00%+2.20%-2.52%-15.17%-16.70%FULCFulcrum Therapeutics0.00%+1.92%+3.05%-52.55%-52.97%SLGLSol-Gel Technologies0.00%-1.49%+12.78%+9.53%+724.55%TRDAEntrada Therapeutics0.00%-15.09%-18.18%-53.68%-8.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.64-4.1%$4.77$3.16▼$11.89$62.50M-0.91287,087 shs78,014 shsFULCFulcrum Therapeutics$3.72-1.1%$4.25$2.83▼$15.74$247.87M3.011.81 million shs572,842 shsSLGLSol-Gel Technologies$81.96+1.8%$74.88$10.48▼$97.97$230.30M1.1235,715 shs24,517 shsTRDAEntrada Therapeutics$5.85-3.3%$6.79$4.93▼$16.45$227.10M-0.26438,722 shs566,335 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate0.00%+2.20%-2.52%-15.17%-16.70%FULCFulcrum Therapeutics0.00%+1.92%+3.05%-52.55%-52.97%SLGLSol-Gel Technologies0.00%-1.49%+12.78%+9.53%+724.55%TRDAEntrada Therapeutics0.00%-15.09%-18.18%-53.68%-8.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 2.50Moderate Buy$27.33489.08% UpsideFULCFulcrum Therapeutics 1.75Reduce$8.20120.43% UpsideSLGLSol-Gel Technologies 2.67Moderate Buy$197.50140.97% UpsideTRDAEntrada Therapeutics 2.33Hold$17.50199.15% UpsideCurrent Analyst Ratings BreakdownLatest CING, SLGL, TRDA, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/20/2026SLGLSol-Gel Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.007/17/2026FULCFulcrum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026SLGLSol-Gel Technologies MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$285.006/11/2026TRDAEntrada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/8/2026TRDAEntrada Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.006/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$55.00 ➝ $52.006/4/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)6/3/2026FULCFulcrum Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight6/2/2026FULCFulcrum Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeUnderperform ➝ Underweight(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$0.31 per shareN/AFULCFulcrum Therapeutics$80M3.10N/AN/A$6.45 per share0.58SLGLSol-Gel Technologies$19.39M11.88N/AN/A$8.19 per share10.01TRDAEntrada Therapeutics$25.42M8.93N/AN/A$8.01 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$22.45M-$4.23N/AN/AN/AN/A-365.15%-158.55%8/18/2026 (Estimated)FULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)SLGLSol-Gel Technologies-$6.13M-$0.34N/AN/AN/A-5.66%-3.17%-2.58%8/21/2026 (Estimated)TRDAEntrada Therapeutics-$143.75M-$3.99N/AN/AN/A-2,895.05%-51.22%-42.20%8/5/2026 (Estimated)Latest CING, SLGL, TRDA, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2026Q2 2026SLGLSol-Gel Technologies-$2.31N/AN/AN/A$0.15 millionN/A8/18/2026Q2 2026CINGCingulate-$0.63N/AN/AN/A$0.17 millionN/A8/5/2026Q2 2026TRDAEntrada Therapeutics-$1.0493N/AN/AN/A$2.23 millionN/A8/4/2026Q2 2026FULCFulcrum Therapeutics-$0.21N/AN/AN/AN/AN/A5/28/2026Q1 2026SLGLSol-Gel Technologies-$2.86-$1.31+$1.55$1.31$0.90 million$0.11 million5/14/2026Q1 2026CINGCingulate-$0.53-$0.95-$0.42-$0.95N/AN/A5/7/2026Q1 2026TRDAEntrada Therapeutics-$1.06-$0.95+$0.11-$0.95$2.92 million$0.88 million4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A2.552.55FULCFulcrum TherapeuticsN/A34.3334.33SLGLSol-Gel TechnologiesN/A8.848.84TRDAEntrada TherapeuticsN/A13.9013.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%FULCFulcrum Therapeutics89.83%SLGLSol-Gel Technologies26.18%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipCINGCingulate5.30%FULCFulcrum Therapeutics7.30%SLGLSol-Gel Technologies66.51%TRDAEntrada Therapeutics9.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate2013.47 million12.76 millionNot OptionableFULCFulcrum Therapeutics10066.63 million61.77 millionOptionableSLGLSol-Gel Technologies502.81 million941,000No DataTRDAEntrada Therapeutics11038.82 million35.14 millionOptionableCING, SLGL, TRDA, and FULC HeadlinesRecent News About These CompaniesEntrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from BrokeragesJuly 10, 2026 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Trading 1.1% Higher - Still a Buy?July 9, 2026 | marketbeat.comOppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)June 14, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)June 9, 2026 | theglobeandmail.comEntrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 4, 2026 | prnewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyJune 2, 2026 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 2, 2026 | globenewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 StudyJune 2, 2026 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | markets.businessinsider.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 28, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 26, 2026 | globenewswire.comBernhardt Zeiher Buys 5,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) StockMay 22, 2026 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 19, 2026 | globenewswire.comINVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLCMay 18, 2026 | globenewswire.comTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the ...May 18, 2026 | caledonianrecord.comCTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 14, 2026 | prnewswire.comEntrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 AI Stocks That Could Benefit as AI Moves Beyond the Data CenterBy Thomas Hughes | July 5, 2026Shorting the Grid: Bloom Energy’s $25B AI Power PlayBy Jeffrey Neal Johnson | July 2, 2026Sandisk: What the Chart Is Trying to Tell UsBy Sam Quirke | July 17, 2026Why Micron Is Doubling Down While the HBM Shortage PersistsBy Thomas Hughes | July 13, 20263 European Stocks to Carry Investors Through the Back Half of 2026By Chris Markoch | July 1, 2026CING, SLGL, TRDA, and FULC Company DescriptionsCingulate NASDAQ:CING$4.64 -0.20 (-4.13%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.66 +0.02 (+0.32%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Fulcrum Therapeutics NASDAQ:FULC$3.72 -0.04 (-1.06%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.73 +0.01 (+0.22%) As of 07/24/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Sol-Gel Technologies NASDAQ:SLGL$81.96 +1.41 (+1.75%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$82.66 +0.70 (+0.85%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Entrada Therapeutics NASDAQ:TRDA$5.85 -0.20 (-3.31%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.85 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
